Previous studies have suggested that TP53 mutations were associated with worse OS and progression-free survival (PFS) [12–14] and might play an important adverse role in the malignant transformation of MDS to AML [15–17]. The gene discussed is TP53; the disease is myelodysplastic syndrome.